Jul 2013

Home >> Clinical Trials News Archive >> 2013 >> Jul 2013

The Israeli Life Science Industry 2012 Summary Report is out. The report presents an overview of the current status of the Israeli life  sciences industry. It analyzes industry dynamics and trends across a range of sub-sectors and medical fields and provides insights into the future outlook for the industry.

The biotech IPO scene turns red hot. During all of last year there were only 11 biotech IPOs. In the last 6 months, though, the industry has seen a tremendous rebound, with almost twice that number of IPOs in half the time. And there's no sign that the great leap into the public market is waning, with 10 more IPOs in the queue.

Innovation Nation: Israel is flexing its biotech muscles. According to the State of Israel’s Ministry of Industry, the number of life-science companies has grown from 186 in 1996 to more than 1,100 in 2012. Medical-device companies make up almost 50 percent of that pool, and Israel is number one worldwide in medical-device patents per capita. It is also a close second to the United States in biopharma patents per capita.

Philips Healthcare to establish Israeli incubator. "We at Philips need to be more serious about our activity in Israel," said Philips Healthcare Senior VP business development, strategy and M&A Arnaud Bernaert. "There were ideas, which when we first encountered them seemed too advanced for acquisition, and which were ultimately sold to competitors."

Manchester and Israel partnership to boost stem cell and cancer research. A new partnership approach, which will also see combined studies into heart disease, stem cell and genetic research, was agreed by the two world-leading research Centres.

Israel ranked second in KPMG's Global Technology Innovation survey. The next disruptive technology breakthrough will come out of the United States according to a recent survey by KPMG. More than 800 technology business leaders worldwide were asked to identify disruptive technologies and innovation trends to inform the advisory firm’s Global Technology Innovation survey.

US drugmaker Perrigo to buy Ireland's Elan for $8.6bn. US generic drugmaker Perrigo agreed to buy fellow drug company Elan for $8.6bn (£5.6bn) on Monday in a deal that will hand it royalty rights from a blockbuster multiple sclerois treatment and tax savings from being domiciled in Ireland.